Cash Position: Cash, cash equivalents and marketable securities were $332.3M as of June 30. We believe our current cash, cash equivalents and marketable securities are sufficient to fund our planned operations into 2025.”I am proud of our team’s execution during the second quarter as we achieved a number of important milestones, including the completion of patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and completion of patient enrollment in the Phase 2 SERENITY trial of VTX958 in plaque psoriasis,” said Raju Mohan, Chief Executive Officer. “We look forward to reporting topline results for VTX002 in ulcerative colitis early in the fourth quarter of 2023, followed by the topline readout for VTX958 in plaque psoriasis, which is also expected in the fourth quarter of 2023. Meanwhile, we continue to advance our novel NLRP3 inhibitor portfolio, and we are very excited to have recently initiated dosing in a Phase 1 trial of our CNS-penetrant NLRP3 inhibitor VTX3232 in healthy volunteers
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTYX:
- Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
- Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference
- Ventyx Biosciences management to meet virtually with Piper Sandler
- J&J FRONTIER 1 Phase 2 leaves door open for Ventyx’s VTX-958, says Oppenheimer
- Wells Fargo expects Ventyx Biosciences’ shares to work into 2H23 catalysts